Donis-KellerH, DouS, ChiD, CarlsonKM, ToshimaK, LairmoreTC, HoweJR, MoleyJF, GoodfellowP, WellsSAJr. 1993. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet, 2:851–856.
2.
MulliganLM, KwokJB, HealeyCS, ElsdonMJ, EngC, GardnerE, LoveDR, MoleSE, MooreJK, PapiL, PonderMA, TeleniusH, TunnacliffeA, PonderBAJ. 1993. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature, 363:458–460.
3.
RohmerV, Vidal-TrecanG, BourdelotA, NiccoliP, MuratA, WemeauJL, Borson-ChazotF, SchvartzC, TabarinA, ChabreO, ChabrierG, CaronP, RodienP, SchlumbergerM, BaudinE. 2011. Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines. J Clin Endocrinol Metab, 96:E509–518.
4.
EliseiR, RomeiC, RenziniG, BotticiV, CosciB, MolinaroE, AgateL, CappagliV, MiccoliP, BertiP, FavianaP, UgoliniC, BasoloF, VittiP, PincheraA. 2012. The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. J Clin Endocrinol Metab, 97:426–435.
5.
WellsSAJr, RobinsonBG, GagelRF, DralleH, FaginJA, SantoroM, BaudinE, EliseiR, JarzabB, VasselliJR, ReadJ, LangmuirP, RyanAJ, SchlumbergerMJ. 2012. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol, 30:134–141.
6.
WeinsteinIB, JoeA. 2008. Oncogene addiction. Cancer Res, 68:3077–3080discussion 3080.
7.
JacksonCE, BlockMA, GreenawaldKA, TashjianAHJr. 1979. The two-mutational-event theory in medullary thyroid cancer. Am J Hum Genet, 31:704–710.
8.
SimpsonNE, KiddKK, GoodfellowPJ, McDermidH, MyersS, KiddJR, JacksonCE, DuncanAM, FarrerLA, BraschK, CastiglioneC, GenelM, GertnerJ, GreenbergCR, GusellaJF, HoldenJJA, WhiteBN. 1987. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature, 328:528–530.
9.
NelkinBD, de BustrosAC, MabryM, BaylinSB. 1989. The molecular biology of medullary thyroid carcinoma. A model for cancer development and progression. JAMA, 261:3130–3135.
10.
NelkinBD, NakamuraY, WhiteRW, de BustrosAC, HermanJ, WellsSAJr, BaylinSB. 1989. Low incidence of loss of chromosome 10 in sporadic and hereditary human medullary thyroid carcinoma. Cancer Res, 49:4114–4119.
11.
SchmidtL, DuhFM, ChenF, KishidaT, GlennG, ChoykeP, SchererSW, ZhuangZ, LubenskyI, DeanM, AllikmetsR, ChidambaramA, BergerheimUR, FeltisJT, CasadevallC, ZamarronA, BernuesM, RichardS, LipsCJ, WaltherMM, TsuiLC, GeilL, OrcuttML, StackhouseT, LipanJ, SlifeL, BrauchH, DeckerJ, NiehansG, HughsonMD, MochH, StorkelS, LermanMI, LinehanWM, ZbarB. 1997. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet, 16:68–73.
12.
HirotaS, IsozakiK, MoriyamaY, HashimotoK, NishidaT, IshiguroS, KawanoK, HanadaM, KurataA, TakedaM, Muhammad TunioG, MatsuzawaY, KanakuraY, ShinomuraY, KitamuraY. 1998. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 279:577–580.
13.
TakahashiM, CooperGM. 1987. RET transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol Cell Biol, 7:1378–1385.
14.
TakahashiM, RitzJ, CooperGM. 1985. Activation of a novel human transforming gene, RET, by DNA rearrangement. Cell, 42:581–588.
15.
GriecoM, SantoroM, BerlingieriMT, MelilloRM, DonghiR, BongarzoneI, PierottiMA, Della PortaG, FuscoA, VecchioG. 1990. PTC is a novel rearranged form of the RET proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell, 60:557–563.
16.
SantoroM, CarlomagnoF, RomanoA, BottaroDP, DathanNA, GriecoM, FuscoA, VecchioG, MatoskovaB, KrausMH, Di FiorePP. 1995. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science, 267:381–383.
17.
HofstraRM, LandsvaterRM, CeccheriniI, StulpRP, StelwagenT, LuoY, PasiniB, HoppenerJW, van AmstelHK, RomeoG, LipsCJM, BuysCHCM. 1994. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature, 367:375–376.
18.
ForbesSA, BindalN, BamfordS, ColeC, KokCY, BeareD, JiaM, ShepherdR, LeungK, MenziesA, TeagueJW, CampbellPJ, StrattonMR, FutrealPA. 2011. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res, 39:D945–950.
19.
Sanger Institute. COSMIC Catalogue Of Somatic Mutations In Cancer. www.sanger.ac.uk/genetics/CGP/cosmic. 2012 February 2.
20.
MorandiA, Plaza-MenachoI, IsackeCM. 2011. RET in breast cancer: functional and therapeutic implications. Trends Mol Med, 17:149–157.
21.
JuYS, LeeWC, ShinJY, LeeS, BleazardT, WonJK, KimYT, KimJI, KangJH, SeoJS. 2012. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res, 22:436–445.
22.
DawsonDM, LawrenceEG, MacLennanGT, AminiSB, KungHJ, RobinsonD, ResnickMI, KurshED, PretlowTP, PretlowTG. 1998. Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer. J Natl Cancer Inst, 90:519–523.
23.
ZengQ, ChengY, ZhuQ, YuZ, WuX, HuangK, ZhouM, HanS, ZhangQ. 2008. The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer. J Int Med Res, 36:656–664.
24.
RomeiC, UgoliniC, CosciB, TorregrossaL, VivaldiA, CiampiR, TacitoA, BasoloF, MaterazziG, MiccoliP, VittiP, PincheraA, EliseiR. 2012. Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. Thyroid, 22:476–481.
25.
EngC, MulliganLM, HealeyCS, HoughtonC, FrillingA, RaueF, ThomasGA, PonderBA. 1996. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res, 56:2167–2170.
26.
SchillingT, BurckJ, SinnHP, ClemensA, OttoHF, HoppnerW, HerfarthC, ZieglerR, SchwabM, RaueF. 2001. Prognostic value of codon 918 (ATG→ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer, 95:62–66.
27.
EliseiR, CosciB, RomeiC, BotticiV, RenziniG, MolinaroE, AgateL, VivaldiA, FavianaP, BasoloF, MiccoliP, BertiP, PaciniF, PincheraA. 2008. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab, 93:682–687.
28.
SchultenHJ, Al-MaghrabiJ, Al-GhamdiK, SalamaS, Al-MuhayawiS, ChaudharyA, HamourO, AbuzenadahA, GariM, Al-QahtaniM. 2011. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. Anticancer Res, 31:4179–4183.
29.
MouraMM, CavacoBM, PintoAE, LeiteV. 2011. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab, 96:E863–868.
